Single User License
INR 101895
Site License
INR 203790
Corporate User License
INR 305685

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chong Kun Dang Pharmaceutical Corp.-Product Pipeline Review-2015

Chong Kun Dang Pharmaceutical Corp.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Chong Kun Dang Pharmaceutical Corp.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Chong Kun Dang Pharmaceutical Corp.-Product Pipeline Review-2015', provides an overview of the Chong Kun Dang Pharmaceutical Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Chong Kun Dang Pharmaceutical Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Chong Kun Dang Pharmaceutical Corp. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Chong Kun Dang Pharmaceutical Corp.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Chong Kun Dang Pharmaceutical Corp.'s pipeline products

Reasons To Buy

Evaluate Chong Kun Dang Pharmaceutical Corp.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Chong Kun Dang Pharmaceutical Corp. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Chong Kun Dang Pharmaceutical Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Chong Kun Dang Pharmaceutical Corp. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chong Kun Dang Pharmaceutical Corp.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Chong Kun Dang Pharmaceutical Corp. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Chong Kun Dang Pharmaceutical Corp. Snapshot 6

Chong Kun Dang Pharmaceutical Corp. Overview 6

Key Information 6

Key Facts 6

Chong Kun Dang Pharmaceutical Corp.-Research and Development Overview 7

Key Therapeutic Areas 7

Chong Kun Dang Pharmaceutical Corp.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Combination Treatment Modalities 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Chong Kun Dang Pharmaceutical Corp.-Pipeline Products Glance 15

Chong Kun Dang Pharmaceutical Corp.-Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Chong Kun Dang Pharmaceutical Corp.-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Chong Kun Dang Pharmaceutical Corp.-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Chong Kun Dang Pharmaceutical Corp.-Drug Profiles 19

beloranib 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

carvedilol SR 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

CKD-943 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

(amlodipine besylate + candesartan) 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

CKD-941 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

CKD-942 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

CR-845 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

LT-0011 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

CKD-12201 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

CKD-516 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

CKD-519 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

CKD-581 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

CKD-902 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

CKD-903 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

darbepoetin alfa 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

CKD-10101 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

CKD-12101 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

CKD-830 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

CKD-841 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CKD-L 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Nepodin 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Chong Kun Dang Pharmaceutical Corp.-Pipeline Analysis 44

Chong Kun Dang Pharmaceutical Corp.-Pipeline Products by Target 44

Chong Kun Dang Pharmaceutical Corp.-Pipeline Products by Route of Administration 46

Chong Kun Dang Pharmaceutical Corp.-Pipeline Products by Molecule Type 47

Chong Kun Dang Pharmaceutical Corp.-Pipeline Products by Mechanism of Action 48

Chong Kun Dang Pharmaceutical Corp.-Recent Pipeline Updates 49

Chong Kun Dang Pharmaceutical Corp.-Dormant Projects 54

Chong Kun Dang Pharmaceutical Corp.-Company Statement 55

Chong Kun Dang Pharmaceutical Corp.-Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

Chong Kun Dang Pharmaceutical Corp., Key Information 6

Chong Kun Dang Pharmaceutical Corp., Key Facts 6

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Indication, 2015 9

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Stage of Development, 2015 10

Chong Kun Dang Pharmaceutical Corp.-Monotherapy Products in Pipeline, 2015 11

Chong Kun Dang Pharmaceutical Corp.-Combination Treatment Modalities in Pipeline, 2015 12

Chong Kun Dang Pharmaceutical Corp.-Partnered Products in Pipeline, 2015 13

Chong Kun Dang Pharmaceutical Corp.-Partnered Products/ Combination Treatment Modalities, 2015 14

Chong Kun Dang Pharmaceutical Corp.-Phase III, 2015 15

Chong Kun Dang Pharmaceutical Corp.-Phase II, 2015 16

Chong Kun Dang Pharmaceutical Corp.-Phase I, 2015 17

Chong Kun Dang Pharmaceutical Corp.-Preclinical, 2015 18

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Target, 2015 45

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Route of Administration, 2015 46

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Molecule Type, 2015 47

Chong Kun Dang Pharmaceutical Corp.-Pipeline Products by Mechanism of Action, 2015 48

Chong Kun Dang Pharmaceutical Corp.-Recent Pipeline Updates, 2015 49

Chong Kun Dang Pharmaceutical Corp.-Dormant Developmental Projects,2015 54

Chong Kun Dang Pharmaceutical Corp., Other Locations 56

List of Figures

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Top 10 Indication, 2015 8

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Stage of Development, 2015 10

Chong Kun Dang Pharmaceutical Corp.-Monotherapy Products in Pipeline, 2015 11

Chong Kun Dang Pharmaceutical Corp.-Partnered Products in Pipeline, 2015 13

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Top 10 Target, 2015 44

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Top 10 Route of Administration, 2015 46

Chong Kun Dang Pharmaceutical Corp.-Pipeline by Top 10 Molecule Type, 2015 47

Chong Kun Dang Pharmaceutical Corp.-Pipeline Products by Top 10 Mechanism of Action, 2015 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Chong Kun Dang Pharmaceutical Corp.; Chong Kun Dang Pharmaceutical Corp. - Key Therapeutics; Chong Kun Dang Pharmaceutical Corp. - Pipeline Overview and Promising Molecules; Chong Kun Dang Pharmaceutical Corp. - News; Chong Kun Dang Pharmaceutical Corp. - Latest Updates; Chong Kun Dang Pharmaceutical Corp. - Pipeline; Chong Kun Dang Pharmaceutical Corp. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com